Bailard’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Bailard’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-109,000	Closed	-$3.26M	–	315
2017 Q2	$3.26M	Hold	109,000	–	–	0.26%	97
2017 Q1	$2.89M	Buy	109,000 +9,500	+10%	+$235K	0.24%	101
2016 Q4	$2.21M	Buy	99,500 +13,000	+15%	+$243K	0.2%	115
2016 Q3	$1.6M	Hold	86,500	–	–	0.15%	133
2016 Q2	$1.41M	Hold	86,500	–	–	0.17%	135
2016 Q1	$1.22M	Buy	+86,500	New	+$1.17M	0.17%	89

Other funds holding NDRM

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

SAM

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

CFIC

City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Bailard's NDRM Position: Q3 2017 in Review

Bailard sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 109,000 shares — an estimated $3.26M sold.

Bailard first reported a position in NDRM in Q1 2016 and held it in 6 quarters. The position peaked at $3.26M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

Bailard reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Bailard sold 109,000 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $3.26M.
Bailard first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2016 and held it in 6 quarters.
Bailard's NeuroDerm Ltd. Ordinary Shares position peaked at $3.26M in Q2 2017.
81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Bailard's 13F filing for Q3 2017, filed 11 Oct 2017.